180-day exclusivity rule on hold
"With the recent court decisions, not only already acted upon but pending, as well as the McCain/Schumer bill, things are very, very open to changing," OGD's Davis said. FDA's "180-day final rule for all intents and purposes right now is on hold." McCain/Schumer would allow rolling exclusivity (1"The Pink Sheet" May 7, p. 8)
You may also be interested in...
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials